Comparing effectiveness of Centchroman and Tamoxifen in mastalgia: a randomised control trial
Phase 4
Completed
- Conditions
- Health Condition 1: R52- Pain, unspecified
- Registration Number
- CTRI/2021/01/030206
- Lead Sponsor
- AIIMS Bhubaneswar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 56
Inclusion Criteria
breast pain for more than 3 months
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method breast painTimepoint: 1month, 2month, 3 month and 6th month
- Secondary Outcome Measures
Name Time Method Recurrence of SymptomsTimepoint: 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which Centchroman and Tamoxifen alleviate mastalgia symptoms in R52 pain patients?
How does the efficacy of Centchroman compare to Tamoxifen as a standard-of-care treatment for cyclical and non-cyclical mastalgia?
Are there specific biomarkers that can predict differential response to Centchroman versus Tamoxifen in breast pain management?
What are the known adverse event profiles and management strategies for Centchroman in comparison to Tamoxifen for mastalgia?
What are the potential combination therapies involving Centchroman or Tamoxifen for refractory mastalgia cases?